The AI scribe label has become too broad to be useful. In 2026, it covers at least three distinct product categories with different users, different outputs, different safety profiles, different governance requirements, and different commercial models. Treating them as one market leads to confusion — and potentially to procurement, adoption, and safety decisions based on the wrong assumptions.
Category 1: Clinician-Side Documentation Scribes
These are the dominant and most mature category: ambient AI tools that listen to clinical consultations and produce documentation for the clinician to review and save to the medical record. The market leaders have raised significant capital: Abridge ($250M, ~100 US health systems), Suki ($70M Series D, 300+ health systems), Nuance/Dragon Copilot (Microsoft, 600,000+ clinicians), Heidi Health ($65M Series B, 1 in 2 UK GPs, $465M valuation), Accurx Scribe (Tandem-powered, 200,000+ NHS staff), Tortus (3,500+ UK practices), and Commure ($70M at $7B valuation, broader healthcare AI workflow).
The user is the clinician. The output enters the permanent medical record. Governance includes medical device classification, clinical safety standards, organisational IG, and patient transparency. Kin Health estimates clinician-side scribe adoption has reached 75-90% within major US health systems — a remarkable penetration rate for a technology category that barely existed three years ago.
Category 2: Patient-Side Memory Scribes
This is the emerging category that Kin Health ($9M seed, May 2026) and Aide Health Mirror (UK, October 2025) represent. These tools capture the same consultation but produce patient-facing summaries: plain-language explanations, action items, caregiver sharing, and care navigation.
The user is the patient. The output does not enter the medical record. Governance is different: patient-initiated recording, consumer data privacy, and the patient's right to record for personal use. As TechCrunch noted, clinician-facing scribes "don't do much for patients" — Kin is targeting that gap.
The business models also differ. Clinician scribes are typically sold to healthcare organisations or individual clinicians via subscription. Patient scribes may be free (Kin's model), with monetisation via downstream referrals, labs, and prescriptions — or NHS-adjacent (Aide's model), with adoption through health-system integration.
Category 3: Clinical Reasoning and Evidence Tools
This is where clinical decision support, guideline retrieval, calculators, exam preparation, and CPD sit. These tools do not capture consultations. They help clinicians reason about clinical questions, verify management against evidence, and learn. They are not scribes at all — but the "clinical AI" umbrella increasingly groups them together with documentation tools, creating confusion.
iatroX sits here: source-grounded clinical answers from UK authoritative sources, 80+ calculators with guideline references, 15+ exam Q-banks across UK, US, Canadian, Australian, and Italian curricula, and CPD for reflective practice. The trust model is citation-first: the clinician sees where the answer came from and can verify it.
Why the Stack Will Converge
Today these are separate products bought by separate users through separate procurement channels. Tomorrow they will likely converge into integrated clinical workflows: the scribe documents, the patient receives a summary, the evidence tool surfaces relevant guidelines, the calculator scores the risk, and the CPD tool captures the learning — all from the same consultation.
The winners will be the tools that earn trust through provenance, accuracy, governance proportionate to clinical impact, and workflow fit — appearing where users actually work rather than requiring separate logins, separate tabs, and separate mental models.
Ask iatroX is not a scribe. It is a clinical knowledge layer designed around provenance.